Tags

Type your tag names separated by a space and hit enter

Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19.
Pharmacol Ther. 2020 12; 216:107672.P&T

Abstract

Chloroquine (CQ) and Hydroxychloroquine (HCQ) have been commonly used for the treatment and prevention of malaria, and the treatment of autoimmune diseases for several decades. As their new mechanisms of actions are identified in recent years, CQ and HCQ have wider therapeutic applications, one of which is to treat viral infectious diseases. Since the pandemic of the coronavirus disease 2019 (COVID-19), CQ and HCQ have been subjected to a number of in vitro and in vivo tests, and their therapeutic prospects for COVID-19 have been proposed. In this article, the applications and mechanisms of action of CQ and HCQ in their conventional fields of anti-malaria and anti-rheumatism, as well as their repurposing prospects in anti-virus are reviewed. The current trials and future potential of CQ and HCQ in combating COVID-19 are discussed.

Authors+Show Affiliations

Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA. Electronic address: zining.lei14@stjohns.edu.Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA. Electronic address: zhuoxun.wu17@stjohns.edu.Key Laboratory of medical electrophysiology of education ministry, School of Pharmacy, Southwest Medical University, China; Shenzhen Public Service Platform on Tumor Precision Medicine and Molecular Diagnosis, Southern University of Science and Technology, Shenzhen 518020, Guangdong, China.Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA. Electronic address: yangd1@stjohns.edu.Department of Research, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, Guangdong, China. Electronic address: kezunfu@mail.sysu.edu.cn.Key Laboratory of medical electrophysiology of education ministry, School of Pharmacy, Southwest Medical University, China; Shenzhen Public Service Platform on Tumor Precision Medicine and Molecular Diagnosis, Southern University of Science and Technology, Shenzhen 518020, Guangdong, China. Electronic address: zouchang.cuhk@gmail.com.Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA. Electronic address: chenz@stjohns.edu.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

32910933

Citation

Lei, Zi-Ning, et al. "Chloroquine and Hydroxychloroquine in the Treatment of Malaria and Repurposing in Treating COVID-19." Pharmacology & Therapeutics, vol. 216, 2020, p. 107672.
Lei ZN, Wu ZX, Dong S, et al. Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. Pharmacol Ther. 2020;216:107672.
Lei, Z. N., Wu, Z. X., Dong, S., Yang, D. H., Zhang, L., Ke, Z., Zou, C., & Chen, Z. S. (2020). Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. Pharmacology & Therapeutics, 216, 107672. https://doi.org/10.1016/j.pharmthera.2020.107672
Lei ZN, et al. Chloroquine and Hydroxychloroquine in the Treatment of Malaria and Repurposing in Treating COVID-19. Pharmacol Ther. 2020;216:107672. PubMed PMID: 32910933.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. AU - Lei,Zi-Ning, AU - Wu,Zhuo-Xun, AU - Dong,Shaowei, AU - Yang,Dong-Hua, AU - Zhang,Litu, AU - Ke,Zunfu, AU - Zou,Chang, AU - Chen,Zhe-Sheng, Y1 - 2020/09/08/ PY - 2020/06/30/received PY - 2020/08/28/revised PY - 2020/08/31/accepted PY - 2020/9/11/pubmed PY - 2020/12/2/medline PY - 2020/9/10/entrez KW - COVID-19 KW - Chloroquine (CQ) KW - Hydroxychloroquine (HCQ) KW - Malaria SP - 107672 EP - 107672 JF - Pharmacology & therapeutics JO - Pharmacol Ther VL - 216 N2 - Chloroquine (CQ) and Hydroxychloroquine (HCQ) have been commonly used for the treatment and prevention of malaria, and the treatment of autoimmune diseases for several decades. As their new mechanisms of actions are identified in recent years, CQ and HCQ have wider therapeutic applications, one of which is to treat viral infectious diseases. Since the pandemic of the coronavirus disease 2019 (COVID-19), CQ and HCQ have been subjected to a number of in vitro and in vivo tests, and their therapeutic prospects for COVID-19 have been proposed. In this article, the applications and mechanisms of action of CQ and HCQ in their conventional fields of anti-malaria and anti-rheumatism, as well as their repurposing prospects in anti-virus are reviewed. The current trials and future potential of CQ and HCQ in combating COVID-19 are discussed. SN - 1879-016X UR - https://www.unboundmedicine.com/medline/citation/32910933/Chloroquine_and_hydroxychloroquine_in_the_treatment_of_malaria_and_repurposing_in_treating_COVID_19_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0163-7258(20)30202-3 DB - PRIME DP - Unbound Medicine ER -